Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Getinge, Audiocast, Q4'25

By Inderes1/27/2026, 9:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:01 - 07:17

Thank you very much and welcome, everyone, to today's earnings call. Here with me. I have our CFO, Agneta Palmér. We will start the conference today with our performance in the fourth quarter and then reflect a bit on the full year and our expectations for 2026 and onwards before ending with a Q&A so we can move directly to page number two, please. So let's first look at the development of our longer-term strategic KPIs. You can see here that we continue to clearly track, in line with our plans to increase the share of sales from recurring revenue, accelerating the share of sales from high-margin products like our Paragon offering or ECLS portfolio, the consumables with infection control, and also Bio-Processing bags inside our sterile transfer segment in Life Science. So this is all supported by solid and effective quality processes, which is obviously extremely important in our industry. Sales from recurring revenue now make up about two thirds and high-margin products a little bit more of total revenue. When it comes to quality, the number of field actions in relation to sales has decreased significantly, and we see this positive trend also sequentially continue in the fourth quarter. These improvements should, of course, be achieved through responsible leverage and attractive long-term return on invested capital. We can move to page number three, please. So if we then zoom in on the fourth quarter of last year and some of the key takeaways from the quarter, we managed to beat last year's record quarter and grow top line organically, which I think is really good. Net sales grew by 1.2% organically, with positive development in most BAs and regions, and our order intake increased 2.3% organically. We then look at adjusted gross and EBITDA margins. They were down in the quarter, mainly due to the strong headwind from currency and tariffs and adjusting for the over 1.2 billion currency and tariff headwind in 2025. The EBITDA margin for the full year was considerably higher than 2024, signaling that the underlying performance of the business is strong and developing according to plan. We have solid cash flow and we remain in a very strong financial position with our financial leverage well below two and a half times EBITDA. And the board has. The board of directors has proposed a dividend of $4.75 per share. We can then move to page number four, please. So, if we then look at some of the key activities and events in the quarter and start with what we offer our customers, it's usually our strongest quarter, with a significant amount of shipments. That went out in the last week of the quarter, last week of the year. So a really good collaboration with our customers overall, and this is the reason we managed to reach record high organic sales in the quarter as well. I'm also very happy to see that our intense product development efforts have resulted in several important product launches during the quarter. In Life Science, we have announced the integration of Siemens' open and flexible user interface in the new generation of washer slicers, and this will support streamlined operations, efficient data management, and secure data integrity for our customers across both Life Science and Surgical Workflows. We launched the utility-efficient Aquadis 44 washer-disinfector, which helps hospitals reduce costs and meet their environmental targets. We also launched Automatiq, which is a new family of next generation automated solutions that combines smart robotics, intelligent conveyor systems and advanced software to achieve safer, more consistent and less labor-intensive sterile reprocessing. If we then look at the sustainability and quality aspect of this, we continue to make good regulatory progress in the quarter in our implants business. We received pre-market approval for the iCast covered stent in large diameter for two new lengths. So this will help us become more competitive in the US market, and our PLS set is used in extracorporeal circulation for cardiac and pulmonary support. We see a CE certificate under the EU MDR, and are also happy to see that PiCCO is minimally invasive. Hemodynamic monitoring system is now included in the European Society of Intensive Care Medicine guideline on circulatory shock. I also want to highlight again that our quality KPIs such as audit findings per audit for quality systems and also field actions in relation to sales continue to trend positively. So those are the main activities and events for the fourth quarter. And we can then move to page number five. So looking at our top line performance, we can see that we had solid progress in Acute Care Therapies and in Surgical Workflows. Order intake grew 2.3% organically. And in Acute Care Therapies. This increase was mainly attributable to good performance in ECLS consumables in Transplant Care. And we also saw growth in endoscopic vessel harvesting and in Intra-Aortic Balloon Pump. Organic order intake declined in the quarter due to softer development in WIS, which is our washer isolator sterilizer business and also within Bio-Processing. The organic order intake for Surgical Workflows grew strongly in the quarter, mainly on the back of strong development in infection control consumables and also operating room equipment, generally within Surgical Workflows. From a sales perspective, we had a 1.2% organic increase in sales, and we had both Acute Care Therapies and Surgical Workflows showing low single-digit growth in organic sales. Acute care therapies. The growth came mostly from good performance when it comes to ventilators. Globally, we saw transplant care with good momentum and also ECLS therapy. Organic net sales increased primarily thanks to growth in operating tables and in infection control consumables. And when we look at Life Science, we had an organic net sales decrease, mainly due to lower sales in Bio-Processing. And in this business, where I mentioned order intake, growth in sterile transfer, which is our most important subcategory in Life Science, continued strong. We can then move over to page number six, and I'll hand over to you, Agneta.

Agneta Palmér
07:18 - 09:40

Thank you Matthias. It's positive to see that our activities come through as strong underlying performance. Despite the very negative impact from tariffs and FX in the quarter, we managed comparatively well with decent margins and unadjusted gross profit for the group. Adjusted gross profit amounted to 5,037 million. The impact in the quarter was primarily due to currency and tariffs. Adjusted gross margin was down by 1.1 percentage points in total, in spite of a healthy contribution from price and mix on adjusted EBITDA, adjusted gross profit's effect on EBITDA margin was -0.5 percentage points. Due to what I just mentioned. Adjusted for currency, opex had a slight impact on the margin in the quarter. FX impacted severely by -1.2 percentage points in the quarter, and all in all, this resulted in an adjusted EBITDA of 1,809,000,000 and a margin of 17.8%. Let's move to page seven, please. We remain in a solid financial position. Free cash flow amounted to 1.2 billion in the quarter compared with last year. Free cash flow was impacted by changes in working capital. At the end of Q4, net debt was 9.8 billion SEK. If we adjust for pension liabilities, we are at 7.5 billion SEK. This brings us to a leverage of 1.5 times adjusted EBITDA, which is well below the 2.5 times which we have set as an internal threshold. If we adjust for pension liabilities, leverage is at 1.1 times adjusted EBITDA. Cash amounted to approximately 3.4 billion by the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's move to page eight, please. And back to you, Matthias.

Mattias Perjos
09:41 - 20:55

We remain in a solid financial position. Thank you, Agneta. Before looking at the full year and ahead. I'd just like to take the opportunity to quickly shift from financial KPIs to some other impactful figures. So at Getinge, my colleagues and I have a lot to be proud of. I think if you look at our products and services in the hands of clinicians and pharmaceutical staff, they really make a true lifesaving impact globally every minute. So this slide just lists a few figures describing some of that impact. And it really explains some of the reasons for the strong customer loyalty that we see year in and year out. So for example, if you look at our operating table business, every fourth operating table globally is from Getinge. And these are used in more than 20 million major surgeries annually. If you look at our new washer in Life Science, it uses 32% less water, 25% less energy. So reducing cost and the climate footprint for our customers. And furthermore, if you look at our unique NAVA ventilation technology. This can cut hospital stays by roughly one third for adult ICU patients. So this is a significant win-win, both for patients and for hospital finances. With that, we can move to page nine, please. So we take a step back and look at 2025. Overall, it was certainly an interesting year in many, many aspects. The year can be summed up in four main themes. First, we have the geopolitical friction such as tariffs and the strong currency headwind that we have seen throughout the year. So this has been a wet blanket not only for Getinge, but for most companies globally. And this is something we also expect to continue to deal with in 2026. Secondly, more specific to Getinge, we've seen really good progress in our important quality remediation work. And thirdly, I'm happy to note that our organic innovation focus has resulted in several product launches throughout the year, which will help us further strengthen our competitive position and the support from our customers. All in all, we continue to show strong underlying performance thanks to our industry-leading products and our team's enduring efforts to, together with our customers, navigate the ongoing political turmoil. We can then move over to page number ten, please. I just wanted to take a moment to zoom in on the headwind from tariffs and FX as well, since this was a significant drag on adjusted EBITDA in Q4 and was almost 500 million. And also, of course, a drag on full year Adjusted EBITA by over 1 billion SEK. So tariffs made up almost 150 million SEK in the quarter and about 370 million for the full year, which for last year was Q2 to Q4. Let's exclude the impact of tariffs and currency. Our adjusted EBITA margin in Q4 would have been 20.3% and 16% for the full year. So this is right at the beginning of our longer term guidance span of 16 to 19%, set for the end of 2028. So this really shows that the underlying improvement work is really having good momentum here. And that's something we look forward to continuing to work with and implement in the coming years. Now we can move over to page 11. Thank you. Just a few comments on the regulatory uplift plan as well, with some of the major milestones coming up here in the year. So at the end of 2024, if we take a step back, we reached the important milestone of clearing the quality record backlog during 2025. Several other regulatory milestones have been reached. I mentioned some examples from Q4 at the beginning of this presentation. We've also made progress in the important regulatory product uplifts of our market-leading devices. CardioSave, which is our Intra-Aortic Balloon Pump in Cardiac Assist, and Cardiohelp, the hardware for ECLS therapy within our cardio business segment. When it comes to CardioSave in key markets, the CE approval is reinstated with conditions since last fall. We hoped to initiate sales by the end of last year, but due to some delay in the shipment of critical components, we've now pushed deliveries to the second quarter of 2026. In the US, we're currently only selling replacement pumps to existing customers, and due to the delay with critical components that I just mentioned, we've also pushed the 510(K) submission to Q2 2026. We had strong order growth for pumps in the quarter, which confirms the leading position in this segment and the trust that our customers have in us. And this is why the submission and the start of deliveries is really a key priority for us. We then move to Cardiohelp. There are no sales restrictions in key markets for the existing Cardiohelp. We and our customers are very excited about the next generation device here, the Cardiohelp two. For this one, we sent in the submission for CE Mark approval in Q4 of 2025. And we expect to be able to initiate the first shipments in Europe during the beginning of this year. In the US, we're only selling to existing customers or customers confirming that they don't have any other viable alternative. The work with the 510(K) submission for the complete Cardiohelp two system is going according to plan and is set for the second half of this year. We can then move to page number 12, please. At the Capital Markets Day in our Capital Markets update in May 2024, we guided for an adjusted EBITDA margin of 16 to 19% by the end of 2028. And I think we're on a steady path of reaching that. And that's despite the very different normal world that we have today compared to 18 months ago. The main drivers that will enable this are related to growth, product mix, and productivity. So if we look at the growth angle of this to begin with. So from the perspective of regulatory approvals and key strategic product launches, we have mentioned some of them here. The example is the next generation ECMO therapy with Cardiohelp two, having no sales restriction for CardioSave, an Intra-Aortic Balloon Pump. And also our low temperature sterilization is something that will materialize during this guidance period. We also expect to get our share of the announced US pharma investments and a recovery in Bio-Processing, and we will, of course, continue our diligent and successful work with realizing price increases every year. From a mixed perspective, it is our strategic intent to steer our business towards a continued rotation to high margin products and consumables. And if possible, we prefer to have products that are made up of high-quality hardware and with captive consumables attached to it. Our strong R&D and innovation pipeline is set to contribute to this development. And then from a productivity perspective, we've already done a lot in several parts of the business with the remaining opportunities in other parts of the company. The heightened, extraordinary quality costs connected to the product remediation of CardioSave and Cardiohelp are expected to go down from the second half of 2026 and then be significantly lower in 2027 and 2028, so this will also support the margin expansion. Furthermore, we will continue with our production excellence efforts, helping us to further optimize our supply chain and remain with tight cost control across the company. So all in all, this supports our assessment that our target for 2028 is well within reach. We can then move over to page 13, please. So what does this mean for 2026 then. And here we see primarily three themes. First, unfortunately we expect the geopolitical friction and the FX headwind to continue in 2026. And so of course will our mitigating efforts. Secondly, a key this year will be to hit the critical quality remediation milestones to enable the product launches that we have in the pipeline as soon as possible. And thirdly, we do expect the solid underlying performance to continue. And we have good momentum across large parts of our business when it comes to this. So in many aspects, quite similar to 2025 and setting us up for an acceleration in 2027 and 28, we can then move to page 14. This takes us to our financial outlook for 2026. As we all know, there are some geopolitical uncertainties that we will need to navigate in the coming years. But based on the underlying demand that we see, our expectation is for an organic net sales growth to be in the range of 3 to 5%, adjusted for the phase out of our Surgical Perfusion product category. Surgical Perfusion is expected to have net sales in 2026, declining from about 250 million to 50 million. Secondly. Can we move on to page 16, please. So, summarizing the quarter, we had organic top-line growth, resulting in record high sales for the quarter. Tariffs and FX continue to be a significant headwind, but we still managed to have margins in line with the 2024 level, really confirming that the underlying performance is developing according to our plans. Our financial position remains solid. We had a good end from a cash flow perspective to 2025. Sorry, 2025. For 2026, we guide for organic net sales growth of 3 to 5%, adjusted for the phase out of Surgical Perfusion, and our priorities remain the same for 2026. So key here is addressing the remaining challenges that we have in our Acute Care Therapies business area. We continue to focus on sustainable productivity improvements and cost consciousness when navigating the geopolitical uncertainty and addressing the impact from tariffs. And a key focus, of course, as always, is to continue creating added value for our customers and really help them serve patients better. With that said, I open up for questions.

Operator
20:56 - 21:16

If you wish to ask a question, please dial Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Oliver Greenberg from Kepler Cheuvreux. So in many aspects, quite similar to 2025 and setting us up for an acceleration in 2027 and 2028, we can then move to page 14.

Oliver Greenberg
21:18 - 21:45

Oh, yeah. Thanks very much for taking my questions. And three for me. I'll probably take them one by one. Matthias, can you just say a word on 2026? You alluded to the fact that there are obviously still headwinds from currencies and I guess also tariffs, maybe a certain annualization effect. Can you just help us to get a kind of feeling for the magnitude of these headwinds. And I think the Street is currently expecting 60 basis points of margin expansion. Is that something you feel comfortable with would be the first question, please.

Mattias Perjos
21:47 - 22:45

As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. So we will have a slightly higher level of tariffs up to a couple of hundred million. So that's something we will need to mitigate. So we're fingers crossed for some tariff stability; at least, the best thing would be if they went away. But we expect to have to live with these tariffs now through 2026. So they will continue to be a factor. We expect around half a billion headwind, at least on the currency side. We do expect the dollar to continue to depreciate, but I am really in no position to make any forward-looking estimates on this. So that's an additional headwind that we will need to find ways of mitigating.

Oliver Greenberg
22:46 - 22:52

As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. But would it be fair that you still feel that you can mitigate those, that there will be a net margin expansion at the end?

Mattias Perjos
22:53 - 22:54

As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. That's our ambition.

Oliver Greenberg
22:55 - 23:07

As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. And then secondly, regarding the mid-term guidance, which you also already delivered in the last call, can you give any insight into whether the upper end is as likely as the lower end? So the full range of the guidance still applies?

Mattias Perjos
23:09 - 24:03

I'm not really in a position to dissect the guidance span now and narrow it down, but I think it's really encouraging to see that without the negative effect from the geopolitical consequences of tariffs and headwinds, we would already be within our guidance range. So the momentum underlying in our business is good. We do feel okay about investment climates among our customers as well. I think treatment needs will continue to grow slowly but support our business growth. And like I mentioned in the presentation phase, our productivity measures across the business are also really showing good momentum. So overall we feel good about the traction towards the higher end of the margin span. But I'm not prepared to make any more detailed analysis or break this down with the probabilities right now.

Oliver Greenberg
24:04 - 24:40

As usual, we never comment on expectations from the capital market here, but from a tariff situation, assuming that they remain the way they are now, I think the maths that we have from 2025 will apply in 2026. Fair enough. And the last question, just because it's always probably a good opportunity to discuss capital allocation. You brought the leverage down quite significantly. Can you just talk about priorities? In the past, you leaned more towards M&A. Can you just provide some color on how open you would be to share buybacks at this point, as I believe this was discussed some time ago. There's always this discussion to what extent Life Sciences is a long-term fit, given that the industry is going to normalize. Do you feel that there's a lot of people knocking at your door for any kind of potential offer, any kind of insight here would be great. In the past, you were more leaning towards M&A.

Mattias Perjos
24:41 - 25:28

I think we definitely have continued inbound interest regarding our Life Science business, but it's not something that we have on the divest list here. We feel like good owners, we like the exposure to this market, and we continue to invest in this part of the business as well. When it comes to capital allocation in general. So M&A remains one area, but we also consider share buybacks. It's a discussion that is continually going on in the board, given the uncertainty that still remains. I think we've seen some examples of this already this year with tariffs coming in or the threat of tariffs, and then being withdrawn until this settles. I think it's. It's good to be a little bit prudent with how we allocate capital.

Oliver Greenberg
25:28 - 25:30

Okay. Thanks so much, Mattias.

Mattias Perjos
25:31 - 25:31

The next question comes from Matthias from CIB.

Operator
25:35 - 25:38

The next question comes from Matthias from CIB. Please go ahead.

Matthias
25:41 - 26:08

Hi. Thanks for taking my questions. I have three; I'll take them one by one. First one, if you could talk a bit about the sort of phasing for the year, for example, assuming perhaps Q1 is one of your tougher comps during 2026 from the perspective of a couple of things. Also, quality costs, it sounds like they should come down primarily towards the second half. So maybe if you could give your view there. That's the first one.

Mattias Perjos
26:10 - 26:33

Yeah. No, we're not prepared to make any kind of quarterly guidance here. But the dynamics you describe, we agree with, and we've guided for 3 to 5% growth in 2026. Our ambition is to continue to expand the margin as well. But I can't really break this down by quarter.

Matthias
26:35 - 27:05

Okay, then. It appears ventilators have been very strong, of course. And strength continued also into Q4, perhaps driven more by outside the US markets. But could you give us your overall thinking for the business in 2026, perhaps without going into too much detail, but more how you think about it going forward: will it be tougher, or is the momentum strong enough to make it continue to grow strongly?

Mattias Perjos
27:05 - 27:53

For 2026, I think I'll describe it the way we've done it during 2025. We've had over a year of good momentum now in this business; I think, definitely compared to our market share pre-this shift, we've been a net beneficiary when it comes to market share grab. So very thankful for the support from our customers and the great work by our teams to make this happen. I think that there is a mix of replacement cycle, the normal replacement cycle going on in this business, and there is the continued withdrawal of some of the remaining incumbents in this business as well. But needless to say, the tailwind will be much, much milder than it was during the end of 24 and the whole of 2025.

Matthias
27:56 - 28:17

It appears ventilators have been very strong, of course. It appears ventilators have been very strong, of course. And then on the situation on the supply side in IBP, what is your level of confidence to have that sorted in Q2? And also, is it fair to say that CardioSave in the US would be sold without restrictions towards the end of 2026, or how do you view that?

Mattias Perjos
28:19 - 28:56

I don't think we will be able to sell without restrictions towards the end of 2026. This is now first about submitting the updated 510(K) that we've said is now in the second quarter. It still hinges on making sure that we have the critical components fully available, that we can do the validation and testing needed and prepare for this. So there is still some uncertainty related to this, but we feel more confident about Q2. Otherwise, we wouldn't have said something different here. So, some remaining work but also steady progress towards this.

Matthias
28:57 - 28:58

I don't think we will disclose the exact growth figures of Paragonix SherpaPak.

Mattias Perjos
28:59 - 29:00

It appears ventilators have been very strong, of course.

Operator
29:03 - 29:07

The next question comes from Christopher Lilienberg from Carnegie. Okay, then.

Christopher Lilienberg
29:10 - 29:26

Hi. It appears ventilators have been very strong, of course. I also ask my questions first. Are you able to comment on Paragonix SherpaPak's performance for 2025? Maybe how much it's growing right now and margins?

Agneta Palmér
29:30 - 29:52

I don't think we will disclose the exact growth figures of Paragonix SherpaPak. We are very happy about this development, and it is visible in our report. We will end up with a bit of a higher earnout also based on this. And margin-wise, it is also developing according to our expectations or a bit better.

Christopher Lilienberg
29:53 - 29:56

But would you say it's still dilutive on margin?

Agneta Palmér
29:59 - 30:05

It's slightly dilutive on margins, overall on the EBITDA margin.

Christopher Lilienberg
30:08 - 30:10

We are very happy about this development, as is visible in our report. For the Group or for a segment?

Agneta Palmér
30:11 - 30:14

For the Group. We are very happy about this development, as is visible in our report. And consequently.

Christopher Lilienberg
30:18 - 30:53

It is difficult to break this down. Then my second question, Matthias asked before about phasing effects. Just wondering about Q1 and the flu season. I think that was quite a good benefit for you last year, and it seems the number of cases is dropping quite fast in the US. Could you maybe give a little bit of flavor on how much a good, strong, or weak flu season impacts sales in a given quarter?

Mattias Perjos
30:55 - 31:21

No. The short answer is no. This is difficult to break it down. There's been a couple of years after the pandemic where we had no flu season effect, and now we saw last year that there was some. This year, if you look at the 2025/2026 season, hospitalizations increased a little bit earlier than before, so there was maybe a bit more of a December effect, but it's impossible for us to speculate about the impact of this in Q1, unfortunately.

Christopher Lilienberg
31:23 - 31:39

We are very happy about this development, and it is visible in our report. And finally, when it comes to the quality cost, is it possible to say approximately how much lower they were in 2025 versus 2024, or if they were still at least 800 plus level?

Agneta Palmér
31:42 - 31:56

No, I think we will stick with the information that we have provided before. We had a peak level; that is, we are remaining at high levels, and it will then slightly come down, but we will not give any exact amounts.

Christopher Lilienberg
31:58 - 32:01

But you can confirm it was less than 800,000,000 in 2025.

Agneta Palmér
32:02 - 32:03

Yes. That we can confirm.

Christopher Lilienberg
32:04 - 32:05

We are very happy about this development, as is visible in our report. We are very happy about this development, as is visible in our report.

Mattias Perjos
32:07 - 32:08

I would like to start with touching upon ventilators again, like we've been talking about a bit before already.

Operator
32:11 - 32:15

The next question comes from Ludwig German from Handelsbanken. Please go ahead.

Oliver Greenberg
32:18 - 32:44

Good morning, Olivier from Handelsbanken. Thank you for taking my questions. I would like to start by touching upon ventilators again, as we've discussed a bit before already. But would you be willing to give some flavor around the ventilator sales? We knew that comps were tough going into this quarter. And yet the sales come out strong. Now, what does this strong mean? What are the main drivers and how should we think about this going into Q1 where dynamics are very similar?

Mattias Perjos
32:47 - 33:05

I think the strength comes on the back of some continued competitive conversion, possibly some of the normal replacement cycle kicking in, and also some flu effect. Possibly. But we can't break this down even if we wanted to, unfortunately.

Oliver Greenberg
33:06 - 33:12

But did it surprise you, or was this in line with what you expected?

Mattias Perjos
33:13 - 33:19

I wouldn't say surprised. Mild surprise. Maybe with a mild positive compared to expectations.

Oliver Greenberg
33:21 - 33:33

But did it surprise you, or was this in line with what you expected? Thank you. And then a quick one on Paragonix SherpaPak. It seems like it's doing well there. Another quarter of strong growth. What are the main drivers you're seeing in Paragonix SherpaPak? What are you expecting for 2026?

Mattias Perjos
33:35 - 33:50

Well, the drivers have not changed. I mean, there is this conversion from ice, is still one of the ongoing things. And then, of course, we've had a good launch of the kidney vault during 2025 as well. So I'd say these are the main contributors.

Oliver Greenberg
33:53 - 34:17

Okay. And then just a final one on the outlook given the updated definition. If my maths are correct, you're adjusting for an estimated headwind of around 57 basis points. How should we think about this in relation to the other? Has anything changed, given the estimated rest of the business, or is this the same as before?

Agneta Palmér
34:20 - 34:29

And the same as before? We have not guided before on 2026. Would you care to elaborate? The question?

Oliver Greenberg
34:30 - 34:52

No, no. Sorry. I'm thinking of the development outlook when you guided for 3 to 5% in 2025. You did that on the basis of something. Do you see the same market development, excluding the Surgical Perfusion.

Agneta Palmér
34:55 - 35:26

There are a number of different dynamics in the market development. Of course, if we look at our market presence, it is the same trajectory as in 2025 and strong in our key positions. And then we have different dynamics such as the one described by Mattias when it comes to ventilators and the conversion effect that is a tough comparison now moving into 2026.

Oliver Greenberg
35:29 - 35:30

Okay, I got it. Thank you.

Operator
35:37 - 35:41

The next question comes from Phillip Agnew from JP Morgan. And then just a final one on the outlook given the updated definition.

Phillip Agnew
35:43 - 35:58

Thank you for taking my question. Firstly on Section 232, we'd love to get your thoughts on that probe and the implications of that. And what you anticipated in terms of its outcome for 2026?

Agneta Palmér
36:02 - 36:38

Yes, I have hopes, but I would not speculate in the outcome. What we can say about Section 232 is that we have submitted our opinion along with our industry colleagues, and we are expecting clarity on this. In Q1, it is what has been said before. So let's hope for some clarity. And as Matthias mentioned before, at the very least, stability on tariffs. That's all we can say on this one.

Phillip Agnew
36:40 - 36:51

And then just a final one on the outlook given the updated definition. Perfect. And then maybe can you remind us of your tariff mitigation actions that you're putting through? And what sort of impact do you expect they can have in 2026?

Agneta Palmér
36:57 - 37:41

And we can just reiterate what we have mentioned before. So we work with it. We always work very actively with pricing, but we intensify these efforts to mitigate for tariffs. We also intensify our productivity agenda. That has also been very strong before. But we have accelerated some areas of that to compensate for the increased cost for tariffs. And then the third bucket is that we review our structure both in terms of our business partners, so to speak, with suppliers, etc. and in some cases also our own footprint.

Phillip Agnew
37:43 - 38:11

Right. Perfect. And then just the last one for me, please. I'm not sure if someone's already asked this because my line cut out. But we saw the profit warning from Teleflex a few weeks ago. And they were talking about weakness in demand for intra-aortic balloon pumps and catheters in the US and Asia. So, just wondering if you had any thoughts on that and if you were seeing anything in your existing customers, or does it change anything with planning for CardioSave?

Mattias Perjos
38:13 - 38:43

Yes, I think we've seen that as well. We can only comment on our reality, and I think our view is a bit muddled by the fact that we have supply restrictions here, but the order intake and the optimism from our customers in terms of getting shipments of balloon pumps started in Q2 now is positive. I'd say so. We have a somewhat positive picture of the demand situation and the desire from our customers to have access to this therapy again.

Phillip Agnew
38:47 - 38:47

Thank you guys.

Mattias Perjos
38:49 - 38:50

Perfect.

Operator
38:53 - 38:58

The next question comes from Sten Gustafson from ABG Sundal Collier. Perfect.

Sten Gustafson
39:00 - 40:02

Good morning. I have a question regarding the margin outlook for the year. You expect to compensate the tariffs and FX and expand margins? I think I understood you correctly. It would be good to hear what assumptions you made on tariffs and also on what type of FX headwinds you expect on EBIT for the year. Have you on the tariff side, have you assumed the tariffs to remain unchanged or, coming back to Section 232, which I think at least partly assumes higher tariffs? So, if you could provide some clarity on what you have included in your internal thinking for the year. That would be helpful.

Mattias Perjos
40:03 - 40:21

Yeah. When it comes to the tariffs, we have assumed the same level as we ended in 2025. We have made no predictions on the outcome of any. 232 investigation here. So, it's the same tariffs that we left 2025 with that we have assumed for this year.

Sten Gustafson
40:23 - 40:32

Thank you. And, in terms of FX headwinds, I think it was 1.2 percentage points in Q4 on EBIT.

Agneta Palmér
40:37 - 40:57

We don't speculate in the FX development, and we will not give any specific guidance on this. But overall, as you know, a weakening dollar is negative for us. And we will do everything that we can to mitigate and compensate for that in the case that that continues, which has been the trend in the start of this year. Thank you.

Sten Gustafson
40:58 - 41:14

Okay, but you're not. Do you think it will be higher than 1.2% for 2026? Or is that a sort of a proxy or what you have assumed the impact will continue to be during the year.

Agneta Palmér
41:16 - 41:27

Again, we will not speculate on the development of the US dollar. So we work with a number of scenarios and mitigation activities and we adjust accordingly.

Sten Gustafson
41:27 - 41:47

It would be good to hear what assumptions you made on tariffs and also what type of FX headwinds you expect on EBIT for the year. And finally, on price, you were successful last year. Raising prices. I think you talked about previously 2 to 3 percentage points. Do you think you can do the same thing this year? Raise prices by 2 to 3%?

Mattias Perjos
41:50 - 42:23

The ambition is closer to two than three. I'd say, is realistic, but the price work continues actively as it has done since 2018 for us. So we will continue this work. And I think you already know the dynamics with long contracts in our industry and so on, and limited ability to maneuver in the beginning of this phase. But hopefully there'll be some opportunities there. But ambition is still to continue to improve prices in 2026.

Sten Gustafson
42:23 - 42:25

Perfect. So we will continue this work.

Mattias Perjos
42:26 - 42:27

Thank you.

Operator
42:30 - 42:34

The next question comes from Eric Castle from Danske Bank. Okay.

Eric Castle
42:36 - 43:07

Hello. Morning, everyone. First, I want to touch upon the guidance as well. As you alluded to, Mattias, excluding headwinds from FX and tariffs, you've already reached the low end of the targets you set. Would you say that you've managed to achieve all the improvements you set out to do earlier than planned, meaning that there's not much left to do. Or would you rather say that you underestimated the level of margin improvement you could achieve over time?

Mattias Perjos
43:09 - 43:27

We have definitely not run out of improvement initiatives. There's plenty to do still. I don't want that to imply that we had underestimated the potential either. We know that there is a lot of potential in the business, and we've made some good progress now, as you've seen in 2025. But there's a lot still to do.

Eric Castle
43:30 - 43:57

So we will continue this work. I guess that sounds good that you're not done. Then I want to ask what's happening with the business in terms of drag on margins. Do you keep the organization there to support customers in 2026 and see it become loss making? Or have you already moved a lot of the people over to the ECMO so that there's not much of an effect for ACT as a whole.

Agneta Palmér
44:00 - 44:10

You do expect a slight marginal improvement effect coming from the gradual exit of Surgical Perfusion in 2026.

Eric Castle
44:13 - 44:13

The next question comes from Eric Castle from Danske Bank.

Mattias Perjos
44:13 - 44:26

As you alluded to, Mattias, excluding headwinds from FX and tariffs, you've already reached the low end of the targets you set. We have moved people out already from this business, both to refocus them on our core business. But also there is a reduction of people related to this that we implemented in 2025.

Eric Castle
44:28 - 44:48

Okay, great. And then lastly on ECMO seems to be doing pretty well. How much would you attribute that to? Just the underlying market doing well, perhaps a strong influenza season coming early? Or is there some sort of aspect of you maybe getting back to market share? That is driving the above-market growth?

Mattias Perjos
44:50 - 45:25

It's not possible for us to dissect this. It's very difficult to monitor competitor performance in detail, I think. So we've definitely benefited from good overall market momentum, a little bit of a flu effect in there as well. I think it confirms our competitive products, and that they perform vital life-saving work every day. That's something that's appreciated by the clinicians who are our customers. So this is the main reason why we continue to see growth above the exact market growth in Q4. It's not possible to say right now.

Eric Castle
45:28 - 45:54

Okay, great. And then, lastly, on ECMO, it seems to be doing pretty well. Just lastly, do you have any comments or thoughts on the sort of long-term prospects of ECMO? Now, I recall you saying that there's still a risk that you're going to lose out on customers from them switching. Have you seen any more evidence of that? to provide support that you're really going to lose market share going forward, or maintain or even improve. Do you have a different view now?

Mattias Perjos
45:55 - 46:34

No, I think nothing has changed in our view. We still believe in a longer-term market growth of mid to high single digit for this segment. And looking at the competitive dynamics right now, it doesn't appear that we are losing anything to competitors. So we remain strong with our customers in this segment, and all the work that goes into both launching Cardiohelp two in key markets and also getting the 510(K) submission into the US represents really key milestones now to continue to grow this business.

Eric Castle
46:36 - 46:37

Great. Thank you very much.

Mattias Perjos
46:39 - 46:39

And then lastly, on ECMO, it seems to be doing pretty well.

Operator
46:43 - 46:48

The next question comes from Philipp Wetterqvist from SEB Markets. Please go ahead.

Philipp Wetterqvist
46:50 - 47:11

Good morning. I just have one question on Life Science and then a follow-up. Would you say that what we're seeing in Life Science is, in effect, like a big pharma production ramp up last year ahead of tariffs, leading to some cooler demand this year? Or is it just the lumpiness of the business?

Mattias Perjos
47:13 - 47:45

I think it is partly natural lumpiness of the business. But we have seen also throughout 2025 that there's been a lot of delayed decision-making when it comes to projects. So a lot of companies now have announced expansion plans, but they've not really started to implement projects. So we can see that we have a similar win ratio as we've had before. But there's been less or fewer big opportunities in 2025 due to customer hesitation on the back of geopolitical uncertainty.

Philipp Wetterqvist
47:47 - 47:58

Do you have any idea how much the government shutdown affected Life Science in the quarter, as no NIH funding was paid out during the period?

Mattias Perjos
48:00 - 48:02

No way. We cannot quantify that, unfortunately.

Philipp Wetterqvist
48:03 - 48:04

I just have one question on life science and then follow up. I just have one question on Life Science and then a follow-up.

Mattias Perjos
48:06 - 48:06

I just have one question on Life Science and then a follow-up.

Operator
48:09 - 48:13

The next question comes from Delphine Le from Bernstein. The next question comes from Delphine Le from Bernstein.

Delphine Le
48:16 - 49:04

I just have one question on Life Science and then a follow-up. I just have one question on life science and then follow up. I just have one question on Life Science and then follow up. Good morning. I'll go again, one by one. Just a clarification on the Paragonix SherpaPak. And just wanting to know how big Paragonix is now in the Acute Care Therapies business. How much does that represent? I know you don't want to disclose that, but probably you can give us a sort of a sense and the range of how big it is. Second question to deal with Paragonix, because I didn't catch you mentioned it was not dilutive at the group level. And so, if I'm hearing correctly, I just need a confirmation. And so my question here would be what is missing or when can you achieve sort of the target margin for that specific range of product. And then I will continue.

Mattias Perjos
49:05 - 49:46

I think from a volume perspective, we don't hand out details for subsegments, but it's well over $100 million. Now that Paragon business for us. And what Agneta said earlier is that it's slightly dilutive to group margins and consequently also dilutive to EBITA margins. We don't guide for when it's going to be accretive to margins. And this is more about how we pace the expansion of the business. Really? So we're happy with the performance right now, both from a growth perspective. And we can see that there is operating leverage in the business. But we're also continuing to invest quite a lot, both in the US, in the US expansion and in the future R&D pipeline.

Unknown 2
49:48 - 49:50

I think Bio-Processing, as we have highlighted, was a weak spot for us in Q4. Now, regarding the Paragon business for us. Thank you very much.

Delphine Le
49:50 - 50:09

Moving on, probably to what's going on in China and any feedback you may give us regarding the grants that you have in China, on the hospital activity, on the evolution of the commercial interaction over the course of 2025. Have you anything specific to tell us about that?

Mattias Perjos
50:11 - 51:11

Yeah, I think it's a year of more of the same. I think the hurdles continue to be the same ones that we've battled for a number of years now. We have some really strong positions in China. And I think one of the bright spots is that we actually did grow in China also in 2025. That's not something we take for granted in our industry anymore. So that's really positive and confirms the strong positions that we have going forward. I think again, the geopolitical friction and its impact here will continue to be somewhat of a hurdle. And of course, there are barriers when it comes to having local presence and so on. And there's also, of course, an evolving competitive landscape in China. So basically, we stand by the comments that we've made before that we have a long-term positive view on China. But it has changed quite a lot from five years ago when we had good double-digit growth in that market.

Delphine Le
51:14 - 51:58

Now, the Paragonix business for us. Moving on to the life science. Obviously, we hear from the competition and on the biomanufacturing side speaking about a very nice normalization and a return to high single-digit, low double-digit growth. So I was wondering on your side if you are seeing any traction from the clients? If you confirm, because you're probably a bit more late stage, that the normalization has happened and that you're hearing probably more positive coming out from the US versus Europe, or any comments here, either on a product or on a region, would be interesting.

Mattias Perjos
51:59 - 52:32

I think Bio-Processing, as we have highlighted, was a weak spot for us in Q4. It has been a weak spot throughout 2025, and we have, relative to many of our peers in the market, a higher exposure to China, which has been a more difficult market both from an investment and competitive standpoint. But we do see, from a broader basis, the comeback in other markets than China, like the US for example. So I think that market dynamic we do see as well, but we have a slightly different exposure than many of our peers.

Delphine Le
52:34 - 53:15

Yeah. So I just wonder what the lead times typically are for these products and how much one should look at this Q4 order intake number when predicting sales for H1 2026. And, just returning to the tariff and the mitigation measures that you are currently implementing. Can we get your first feedback on client reactions to the price increase? And can you probably more specify over the course of 2026 how you're going to mitigate exactly the tariff, and what would be the ideal target by the end of the year for 2026, when it comes to the mitigation of the tariff, would that be 50%, 70%? And then thinking about 2027 and 2028?

Mattias Perjos
53:17 - 54:15

I think we've continued working actively with pricing since 2018, when we were able to reverse a downward trend to price improvement. And we've been able to do that ever since. So it's really not something new for us. So there are no new customer reactions to this; customers understand our perspective when it comes to the impact of tariffs, but they also have, of course, a daily reality with their challenges. So it's a dialogue customer by customer, and very different reactions and understanding of this. But we feel that we can continue to work with pricing the way that we have done the last few years successfully here. So that's really the main way. And if you take a couple of percentage points price increases, you can calculate the mitigation effect of that when it comes to tariffs and of course currency.

Delphine Le
54:17 - 54:20

It has been a weak spot throughout 2025, and we have, relative to many of our peers in the market, a higher exposure to China, which has been a more difficult market both from an investment and competitive standpoint. Got your point. Thank you. Thank you very much.

Mattias Perjos
54:21 - 54:21

Can we get your first feedback, clients' reaction about the price increase?

Operator
54:25 - 54:29

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
54:31 - 54:52

Hi. Thank you for taking my questions. So I have two and I take them one by one first on Life Science. So, yeah, weak order intake here in Q4. So I just wonder what the lead times typically are for these products and how much one should look at these Q4 order intake numbers when predicting sales for H1 2026.

Mattias Perjos
54:54 - 55:15

I think on average, the lead time in life science is 9 to 12 months. Having said that, I think in sterile transfer it's much, much quicker given the beta bags, for example. But when it comes to the waste business, it's obviously often over a year in lead time. So the average is 9 to 12 months.

Ludvig Lundgren
55:18 - 55:36

Okay. Thank you very much. Thank you very much. And then second one on this critical component delay, which made you push the 510(K) submission and CE mark launch for CardioSave. I just wonder if you can elaborate a bit on your confidence in this new timeline and if there's any uncertainty in this.

Mattias Perjos
55:39 - 55:55

There is some uncertainty still in this. We still need to make sure that we have adequate supply of the critical components, and that we are able to do the remaining test validations that are required. So it's our best estimate right now. The second quarter for submission.

Ludvig Lundgren
55:58 - 55:59

I think on average, the lead time in life science is 9 to 12 months. Thank you very much.

Mattias Perjos
56:00 - 56:01

Thank you.

Operator
56:03 - 56:22

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Mattias Perjos
56:25 - 56:34

Thank you very much. I think we already made a summary before the Q&A, so nothing in addition to say from me. I just thank you for your attention today and wish you a good rest of the day. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…